Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
semagacestat · 1 trial · 1 indication
The cognitive subscale of the ADAS (ADAS-Cog11) consists of 11 items assessing areas of function most typically impaired in Alzheimer's Disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity.
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. It measures both basic and instrumental activities of daily living. The total score ranges from 0 to 78, with lower scores indicating greater disease severity.
| Arm | Type | Description |
|---|---|---|
| Drug: semagacestat | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| semagacestat | DRUG | 140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability |
Inclusion Criteria: * Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease * Completed semagacestat study LFAN or study LFBC through 88 weeks * Must continue to ...
Top 20 of 24 competitors
Semagacestat is an investigational small molecule being studied for the treatment of Alzheimer's Disease. It is being developed by Eli Lilly and Company (LLY) and has completed a Phase 3 clinical trial. The drug is not approved and remains in clinical development.
Semagacestat is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The drug is an investigational small molecule intended for Alzheimer's Disease.
Semagacestat has completed a Phase 3 clinical trial for Alzheimer's Disease. The trial, NCT01035138, was a completed, uncontrolled study with 180 participants. The drug is investigational and has not been approved by regulatory authorities.
Semagacestat has one completed Phase 3 clinical trial, NCT01035138, titled 'A Study of Semagacestat for Alzheimer's Patients'. The trial enrolled 180 participants across multiple countries including the United States, Australia, Canada, Chile, Finland, France, Germany, Israel, Italy, Japan, Poland, South Africa, Spain, and Sweden.
Semagacestat is not FDA approved. It is an investigational drug that has completed a Phase 3 clinical trial for Alzheimer's Disease. The trial, NCT01035138, was completed, but the drug remains in clinical development and has not been approved for any use.